Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
| ▸ | PDE1A | P54750 | 1/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259058 | 0.90 | PDE4A (0.53) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL4248302 | 0.86 | PDE2A (0.52) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL4250791 | 0.82 | SIRT1 (0.51) | ADORA2A | |
| SCHEMBL3175131 | 0.78 | PDE4A (0.57) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL563378 | 0.76 | ADORA2A (0.52) | ADORA2A | |
| SCHEMBL4251232 | 0.76 | ADORA2A (0.49) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL3177066 | 0.75 | PDE4A (0.54) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL3183622 | 0.75 | PDE4A (0.53) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL4256248 | 0.74 | ADORA2B (0.50) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL3177989 | 0.74 | PDE4A (0.52) | PDE4AADORA2APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | XDH, HCAR1, GPR84 | PDE4A 417/4885ADORA2A 9/4885PDE4B 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.